Now showing items 1-2 of 2

    • Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer 

      D'Andrea, David; Black, Peter C.; Zargar, Homayoun; Zargar-Shoshtari, Kamran; Zehetmayer, Sonja; Fairey, Adrian S.; Mertens, Laura S.; Dinney, Colin P.; Mir, Maria C.; Krabbe, Laura Maria; Cookson, Michael S.; Jacobsen, Niels Erik; Montgomery, Jeffrey S.; Vasdev, Nikhil; Yu, Evan Y.; Xylinas, Evanguelos; Campain, Nicholas J.; Kassouf, Wassim; Dall'Era, Marc A.; Seah, Jo An; Ercole, Cesar E.; Horenblas, Simon; Sridhar, Srikala S.; McGrath, John S.; Aning, Jonathan; Wright, Jonathan L.; Thorpe, Andrew C.; Morgan, Todd M.; Holzbeierlein, Jeffrey M.; Bivalacqua, Trinity J.; North, Scott; Barocas, Daniel A.; Lotan, Yair; Grivas, Petros; Stephenson, Andrew J.; Shah, Jay B.; van Rhijn, Bas W.; Daneshmand, Siamak; Spiess, Philippe E.; Shariat, Shahrokh F. (2020-02-11)
      Objective: To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC). Methods: Complete pathologic response, defined ...
    • A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non–muscle-invasive Bladder Cancer 

      European Association of Urology—Young Academic Urologists Urothelial Carcinoma Working Group; Liu, Kang; Zhao, Hongda; Chen, Xuan; Nicoletti, Rossella; Vasdev, Nikhil; Chiu, Peter Ka-Fung; Ng, Chi Fai; Kawada, Tatsushi; Laukhtina, Ekaterina; Mori, Keiichiro; Yanagisawa, Takafumi; D'Andrea, David; von Deimling, Markus; Alisinni, Simone; Krajewski, Wojciech; Pradere, Benjamin; Soria, Francesco; Moschini, Marco; Enikeev, Dmitry; Shariat, Shahrokh; Kamat, Ashish; Giannarini, Gianluca; Teoh, Jeremy Yuen-Chun (2023-10-11)
      Background Current European Association of Urology (EAU) guidelines support adjuvant intravesical Bacillus Calmette-Guérin (BCG) treatment after Transurethral Resection of Bladder Tumor (TURB) for intermediate- or high-risk ...